首页> 外文OA文献 >A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

【2h】

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

机译：两种P53肽疫苗方法的妇科肿瘤群II期试验：高复发风险卵巢癌患者皮下注射和静脉内脉冲树突细胞

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Osama E. Rahma; Ed Ashtar; Malgorzata Czystowska; Marta E. Szajnik; Eva Wieckowski; Sarah Bernstein; Vincent E. Herrin; Mortada A. Shams; Seth M. Steinberg; Maria Merino; William Gooding; Carmen Visus; Albert B. DeLeo; Judith K. Wolf; Jeffrey G. Bell; Jay A. Berzofsky; Theresa L. Whiteside; Samir N. Khleif;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients [J] . RahmaO.E., AshtarE., CzystowskaM., Cancer immunology, immunotherapy : . 2012,第3期

机译：两种p53肽疫苗方法的妇科肿瘤小组II期试验：高复发风险卵巢癌患者的皮下注射和静脉内脉冲树突状细胞
2. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients [J] . Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Cancer Immunology, Immunotherapy . 2012,第3期

机译：两种p53肽疫苗方法的妇科肿瘤小组II期试验：高复发风险卵巢癌患者的皮下注射和静脉脉冲树突状细胞
3. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma [J] . Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, Journal of Translational Medicine . 2019,第1期

机译：将自体树突状细胞疫苗与具有个性化肽（PEP-DC）或高级高级卵巢血浆癌患者的肿瘤裂解物（OC-DC）进行比较的I / II试验。
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients [O] . Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, -1

机译：两种P53肽疫苗方法的妇科肿瘤群II期试验：高复发风险卵巢癌患者皮下注射和静脉内脉冲树突细胞
6. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma [O] . Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, 2019

机译：将自体树突状细胞疫苗与具有个性化肽（PEP-DC）或高级高级卵巢血浆癌患者的肿瘤裂解物（OC-DC）进行比较的I / II试验。

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

著录项

相似文献

相关主题

期刊订阅